Insider Selling: Tabula Rasa HealthCare Inc (NASDAQ:TRHC) Director Sells $52,600.00 in Stock

Share on StockTwits

Tabula Rasa HealthCare Inc (NASDAQ:TRHC) Director Gordon Tunstall sold 1,000 shares of the business’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $52.60, for a total transaction of $52,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Gordon Tunstall also recently made the following trade(s):

  • On Wednesday, June 19th, Gordon Tunstall sold 1,000 shares of Tabula Rasa HealthCare stock. The shares were sold at an average price of $51.52, for a total transaction of $51,520.00.

TRHC opened at $54.25 on Friday. Tabula Rasa HealthCare Inc has a 1-year low of $40.86 and a 1-year high of $91.16. The company has a current ratio of 1.80, a quick ratio of 1.73 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $1.19 billion, a P/E ratio of 159.56 and a beta of 1.62. The firm has a fifty day moving average of $48.02.

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.14) earnings per share for the quarter, meeting the consensus estimate of ($0.14). Tabula Rasa HealthCare had a negative net margin of 18.15% and a positive return on equity of 4.22%. The firm had revenue of $60.96 million during the quarter, compared to the consensus estimate of $59.24 million. As a group, analysts forecast that Tabula Rasa HealthCare Inc will post -0.55 earnings per share for the current fiscal year.

Several equities research analysts have weighed in on TRHC shares. Piper Jaffray Companies lifted their price target on shares of Beigene to $180.00 and gave the company an “overweight” rating in a research note on Thursday, May 9th. Cantor Fitzgerald started coverage on shares of CytomX Therapeutics in a research note on Monday, May 13th. They issued an “overweight” rating and a $21.00 price target for the company. Guggenheim started coverage on shares of Patterson Companies in a research note on Wednesday, April 17th. They issued a “neutral” rating and a $23.00 price target for the company. Zacks Investment Research raised shares of Vistra Energy from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research note on Saturday. Finally, TheStreet downgraded shares of Twin Disc from a “b-” rating to a “c+” rating in a research note on Tuesday, June 11th. Three equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $82.12.

Large investors have recently bought and sold shares of the company. First Mercantile Trust Co. increased its position in shares of Tabula Rasa HealthCare by 64.5% during the first quarter. First Mercantile Trust Co. now owns 995 shares of the company’s stock worth $56,000 after acquiring an additional 390 shares in the last quarter. South Dakota Investment Council bought a new stake in shares of Tabula Rasa HealthCare during the first quarter worth about $141,000. Belpointe Asset Management LLC bought a new stake in shares of Tabula Rasa HealthCare during the first quarter worth about $172,000. LS Investment Advisors LLC increased its position in shares of Tabula Rasa HealthCare by 11.2% during the first quarter. LS Investment Advisors LLC now owns 3,129 shares of the company’s stock worth $177,000 after acquiring an additional 316 shares in the last quarter. Finally, NumerixS Investment Technologies Inc bought a new stake in shares of Tabula Rasa HealthCare during the first quarter worth about $212,000. 86.68% of the stock is owned by institutional investors.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Featured Article: Forex

Insider Buying and Selling by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Slack  Earns Neutral Rating from Analysts at Credit Suisse Group
Slack Earns Neutral Rating from Analysts at Credit Suisse Group
Slack  Coverage Initiated by Analysts at Morgan Stanley
Slack Coverage Initiated by Analysts at Morgan Stanley
Solaris Oilfield Infrastructure  Coverage Initiated by Analysts at Citigroup
Solaris Oilfield Infrastructure Coverage Initiated by Analysts at Citigroup
Tanger Factory Outlet Centers  Upgraded to “Hold” at Zacks Investment Research
Tanger Factory Outlet Centers Upgraded to “Hold” at Zacks Investment Research
Sterling Bancorp  Coverage Initiated at B. Riley
Sterling Bancorp Coverage Initiated at B. Riley
Restoration Hardware  Upgraded by ValuEngine to “Hold”
Restoration Hardware Upgraded by ValuEngine to “Hold”


© 2006-2019 Ticker Report